logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs' Unit To Acquire Royalties For Bystolic From Janssen Pharmaceutica

Forest Laboratories Inc (FRX) Monday revealed that its wholly-owned subsidiary unit, Forest Laboratories Holdings Limited, has entered into a definitive agreement with Janssen Pharmaceutica NV, wherein the subsidiary unit will acquire all U.S. patents and other U.S. and Canadian intellectual property for Bystolic (nebivolol), which is currently approved in the United States for the treatment of hypertension.

FRX revealed that its subsidiary unit has agreed to make a one-time cash payment of $357 million to Janssen Pharmaceutica NV, and, in turn, Janssen Pharmaceutica will assign all U.S. patents and other U.S. and Canadian know-how covering Bystolic, including the nebivolol composition of matter patent in the U.S. to the subsidiary unit of FRX.

The company further revealed that the subsidiary unit will amortize the one-time cash payment over the remaining patent life of Bystolic.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The Justice Department has initiated a probe to find out if airlines are colluding to limit seating capacity in order to benefit from higher airfares. Saudi Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud has pledged to give away his entire wealth amounting to $32 billion for charity. He said the fund will be utilized for cultural understanding, develop communities, empower women, enable youth, provide vital disaster relief and create a more tolerant and accepting world. Toyota accepted the resignation of its Chief Communications Officer Julie Hamp, following her arrest in Japan for allegedly mailing banned painkillers to her address in Japan from U.S.
comments powered by Disqus
Follow RTT